MX2023007162A - Macrociclos y sus usos. - Google Patents
Macrociclos y sus usos.Info
- Publication number
- MX2023007162A MX2023007162A MX2023007162A MX2023007162A MX2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A
- Authority
- MX
- Mexico
- Prior art keywords
- macrocyclic compounds
- macrocycles
- cancer
- present disclosure
- methods
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126722P | 2020-12-17 | 2020-12-17 | |
| US202163279850P | 2021-11-16 | 2021-11-16 | |
| US202163284789P | 2021-12-01 | 2021-12-01 | |
| US202163289014P | 2021-12-13 | 2021-12-13 | |
| PCT/US2021/063721 WO2022133037A1 (en) | 2020-12-17 | 2021-12-16 | Macrocycles and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007162A true MX2023007162A (es) | 2023-06-29 |
Family
ID=82058646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007162A MX2023007162A (es) | 2020-12-17 | 2021-12-16 | Macrociclos y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182487A1 (https=) |
| EP (1) | EP4262796A4 (https=) |
| JP (1) | JP2023553835A (https=) |
| KR (1) | KR20230121773A (https=) |
| AU (1) | AU2021401741A1 (https=) |
| CA (1) | CA3202770A1 (https=) |
| IL (1) | IL303419A (https=) |
| MX (1) | MX2023007162A (https=) |
| PY (1) | PY21110949A (https=) |
| UY (1) | UY39574A (https=) |
| WO (1) | WO2022133037A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023283476A1 (en) * | 2022-06-08 | 2024-11-14 | Blossomhill Therapeutics, Inc. | Indazole macrocycles and their use |
| CA3258157A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole-Containing Macrocycles and Their Use |
| JP2025524038A (ja) * | 2022-07-27 | 2025-07-25 | 上海和誉生物医薬科技有限公司 | 大環状ｅｇｆｒ阻害剤、その製造方法及び薬学における応用 |
| EP4655304A1 (en) * | 2023-02-22 | 2025-12-03 | Yuhan Corporation | Macrocyclic aminopyridine compounds as egfr inhibitors |
| JP2026507654A (ja) * | 2023-02-22 | 2026-03-04 | ユーハン・コーポレイション | Ｅｇｆｒ阻害剤としての大環状アミノピリジン化合物 |
| KR20250142978A (ko) * | 2023-02-22 | 2025-09-30 | 주식회사유한양행 | Egfr 억제제로서의 마크로시클릭 아미노피리딘 화합물 |
| EP4688750A1 (en) | 2023-04-06 | 2026-02-11 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| AU2024266587A1 (en) * | 2023-05-02 | 2025-09-11 | Blossomhill Therapeutics, Inc. | Egfr inhibitors for treating disease |
| EP4731213A2 (en) * | 2023-06-23 | 2026-04-29 | Blossomhill Therapeutics, Inc. | Combination therapy involving macrocyclic indazole compounds |
| WO2025122911A1 (en) * | 2023-12-07 | 2025-06-12 | Blossomhill Therapeutics, Inc. | Indazole macrocycle polymorphs |
| WO2025122859A1 (en) * | 2023-12-08 | 2025-06-12 | Blossomhill Therapeutics, Inc. | Indazole-based macrocyclic compounds |
| WO2025199438A1 (en) * | 2024-03-22 | 2025-09-25 | Blossomhill Therapeutics, Inc. | 7-azaindazole macrocycles and their use |
| WO2025245175A1 (en) * | 2024-05-22 | 2025-11-27 | Ajax Therapeutics, Inc. | Macrocyclic heteroaromatic inhibitors of jak2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| DK2822953T5 (en) * | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
| CN111269245B (zh) * | 2018-12-04 | 2021-08-27 | 杭州百新生物医药科技有限公司 | 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途 |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
-
2021
- 2021-12-16 WO PCT/US2021/063721 patent/WO2022133037A1/en not_active Ceased
- 2021-12-16 US US18/257,166 patent/US20240182487A1/en active Pending
- 2021-12-16 AU AU2021401741A patent/AU2021401741A1/en active Pending
- 2021-12-16 KR KR1020237021826A patent/KR20230121773A/ko active Pending
- 2021-12-16 MX MX2023007162A patent/MX2023007162A/es unknown
- 2021-12-16 EP EP21907788.0A patent/EP4262796A4/en active Pending
- 2021-12-16 JP JP2023532465A patent/JP2023553835A/ja active Pending
- 2021-12-16 CA CA3202770A patent/CA3202770A1/en active Pending
- 2021-12-16 IL IL303419A patent/IL303419A/en unknown
- 2021-12-17 UY UY0001039574A patent/UY39574A/es unknown
- 2021-12-17 PY PY202121110949A patent/PY21110949A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230121773A (ko) | 2023-08-21 |
| IL303419A (en) | 2023-08-01 |
| AU2021401741A1 (en) | 2023-06-29 |
| US20240182487A1 (en) | 2024-06-06 |
| WO2022133037A1 (en) | 2022-06-23 |
| EP4262796A4 (en) | 2025-04-02 |
| JP2023553835A (ja) | 2023-12-26 |
| EP4262796A1 (en) | 2023-10-25 |
| PY21110949A (es) | 2023-08-07 |
| TW202241911A (zh) | 2022-11-01 |
| AU2021401741A9 (en) | 2024-09-19 |
| CA3202770A1 (en) | 2022-06-23 |
| UY39574A (es) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007162A (es) | Macrociclos y sus usos. | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CL2023000061A1 (es) | Macrociclos y su uso | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2020000169A1 (es) | Compuestos macrocíclicos y usos de los mismos. | |
| UY37272A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| BR112017010188A2 (pt) | análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer | |
| UY39779A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| MX2024014995A (es) | Macrociclos que contienen indazol y su uso | |
| CO2021008117A2 (es) | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina | |
| CO2022014837A2 (es) | Células t v delta1+ para el tratamiento de neoplasias mieloides | |
| MX2024007929A (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| GT200700020A (es) | Compuestos y derivados de dibencilamina | |
| MX2022010945A (es) | Usos terapeuticos de compuestos macrociclicos. | |
| ECSP22093652A (es) | Compuestos de imidazopiridazina y usos de los mismos | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| CL2022002527A1 (es) | Células t v delta1 para el tratamiento de neoplasias mieloides |